Our Services
Medical Information
Helpful Resources
Published on: 9/24/2026
Gwyn Lo is a combination hormonal contraceptive worn as a transdermal patch, delivering estrogen and progestin through the skin to prevent pregnancy. It is pressed onto clean, dry, hairless skin on the upper outer arm, abdomen, buttock, or upper torso (never the breasts), then swapped for a fresh patch on the same day each week for three weeks, followed by one patch-free week. Correct placement, rotating sites, backup contraception timing, and what to do if a patch loosens or falls off all change how well it protects you, so review the important details below before relying on it. If you are dealing with spotting, nausea, headaches, breast tenderness, or mood changes while using the patch, a free, instant, online symptom check can help you sort out what is likely behind it in just a
Is “Gwyn Lo Patch” a Birth Control Patch?
No. There is no FDA-approved contraceptive called the “Gwyn Lo patch.” If you’ve heard this name in conversation or online, it likely refers to a misunderstanding or misspelling of established birth control patches such as Xulane (formerly Ortho Evra) or Twirla. Below, you’ll find clear, reliable information on how hormonal contraceptive patches work and how they’re worn.
A birth control patch is a small, sticky skin patch that releases two hormones—an estrogen (ethinyl estradiol) and a progestin—into your bloodstream. These hormones prevent ovulation (the release of an egg), thicken cervical mucus to block sperm, and thin the uterine lining to reduce the chance of implantation.
Common brand names include:
Despite similar ingredients and action, there is no “gwyn lo patch” on the market. Always check for FDA approval and talk with your pharmacist or provider if you’re unsure about a product name.
Once applied, the patch delivers a steady dose of hormones:
When used correctly, the patch is over 99% effective at preventing pregnancy. Typical use effectiveness is around 91%, largely due to human error (forgetting to change the patch on time, applying it improperly, etc.).
Choose an application site.
Prep your skin.
Apply the patch.
Follow a weekly schedule.
Rotate sites.
Less than 24 hours:
More than 24 hours:
If patches routinely peel off, check your skin prep routine and consider an alternative site.
Most side effects are mild and often improve after 1–2 months:
When to seek medical attention:
These symptoms could be signs of a serious condition. If you experience any, remove the patch and call your doctor right away.
If you’re ever unsure about a symptom or drug interaction, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker. It can help you decide if you need professional care and guide your next steps.
Always speak to a doctor about any serious or life-threatening issues, or if you have questions about your risk factors and the best contraceptive method for you.
(References)
* Yonkers KA, O'Brien PM, Eriksson E. Premenstrual syndrome. Lancet. 2008 Apr 5;371(9619):1200-10. doi: 10.1016/S0140-6736(08)60527-9. PMID: 18395582; PMCID: PMC3118460.
* Peck SA. Long-acting reversible contraception. Nurs Womens Health. 2013 Oct;17(5):431-5. doi: 10.1111/1751-486X.12066. PMID: 24138662.
* Colquitt CW, Martin TS. Contraceptive Methods. J Pharm Pract. 2017 Feb;30(1):130-135. doi: 10.1177/0897190015585751. Epub 2016 Jul 8. PMID: 26033795.
* Lobert M, Pigeyre M, Gronier H, Catteau-Jonard S, Robin G. [Contraception and obesity]. Gynecol Obstet Fertil. 2015 Nov;43(11):740-7. doi: 10.1016/j.gyobfe.2015.09.009. Epub 2015 Oct 31. PMID: 26527416.
* Choice of contraceptives. Med Lett Drugs Ther. 2018 Oct 8;60(1557):161-168. PMID: 30335731.
* Grandi G, Barra F, Ferrero S, Sileo FG, Bertucci E, Napolitano A, Facchinetti F. Hormonal contraception in women with endometriosis: a systematic review. Eur J Contracept Reprod Health Care. 2019 Feb;24(1):61-70. doi: 10.1080/13625187.2018.1550576. Epub 2019 Jan 21. PMID: 30664383.
* Le Guen M, Schantz C, Régnier-Loilier A, de La Rochebrochard E. Reasons for rejecting hormonal contraception in Western countries: A systematic review. Soc Sci Med. 2021 Sep;284:114247. doi: 10.1016/j.socscimed.2021.114247. Epub 2021 Jul 20. PMID: 34339927.
* Nguyen AT, Curtis KM, Tepper NK, Kortsmit K, Brittain AW, Snyder EM, Cohen MA, Zapata LB, Whiteman MK, Contributors. U.S. Medical Eligibility Criteria for Contraceptive Use, 2024. MMWR Recomm Rep. 2024 Aug 8;73(4):1-126. doi: 10.15585/mmwr.rr7304a1. Epub 2024 Aug 8. PMID: 39106314; PMCID: PMC11315372.
* Skeith L, Bates SM. Estrogen, progestin, and beyond: thrombotic risk and contraceptive choices. Hematology Am Soc Hematol Educ Program. 2024 Dec 6;2024(1):644-651. doi: 10.1182/hematology.2024000591. PMID: 39644023; PMCID: PMC11665608.
* Plu-Bureau G, Raccah-Tebeka B. [Contraception and thrombophilia]. Rev Prat. 2025 Mar;75(3):290-292. PMID: 40546174.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.